on 25th, during Rising European Stars Session (from 16.15 to 17.15)
DataHow AG is a spin-off company from ETH Zurich specialized in data analytics and process modeling for the process industry with a particular focus on the production of biopharmaceuticals.
We offer digital solutions and consulting for process screening, monitoring, optimization, control and scale-up. Our goal is to reduce the effort, risks and costs in process development and manufacturing as well as to gain deep understanding of the complex processes.
DataHow emerged in 2017 from the research group of Prof. Morbidelli at ETH Zurich based on the activities of Dr. Alessandro Butté, Michael Sokolov and Fabian Feidl.
At Dicronis, we are developing the first DIY lymphatic activity tracker, featuring a microneedles-covered patch and a wearable detector. The microneedles-mediated skin delivery of a fluorescent agent and the measure of its disappearance rate with a coupled wearable device allows for assessment of the dermal lymphatic function. Being minimally-invasive, painless and simple empower it to be used in a home setting by the patient, and accordingly, allow for a much better monitoring on the lymphatic health. This is highly relevant for basic or nutritional research purposes, to evaluate novel therapeutics or as diagnostic biomarker in diseases where this is disrupted, leading to debilitating consequences. For instance, lymphedema, a condition frequently occurring after cancer treatments, outlined by the swelling of a limb. Early diagnosis of the disease is highly crucial to ensure conservative measures, e.g. lymphatic draining massages or compression garments, are employed early-on for best management of the disease. Indeed, current methods of diagnosis of lymphedema are driven, by the clinical manifestation of the symptoms, which delay disease management and therefore worsen the prognosis.
Hylomorph is a newly formed medical device company based in Switzerland with a breakthrough technology to improve the biocompatibility of medical implants. Upon implantation, devices such as cardiac implantable electronic devices or breast implants are perceived as a foreign body resulting in the formation of fibrotic (scar) tissue around the implant over time. This can lead to severe complications both for patient and surgeon during revision surgery resulting in additional costs of care.
Hylomorph has developed a novel material from biocellulose which has a unique macro and micro morphology disrupting both protein and fibroblast adhesion, blocking the process of fibrotic capsule formation. This material can be formed into a variety of shapes which can be placed around the implantable device, both acting as a physical barrier and an active anti-fibrotic membrane.
Hylomorph is applying this technology to the two largest implantable medical device markets: cardiac implantable electronic devices, and breast implants, aiming to reduce significantly the clinical and economic problems associated with fibrotic capsule formation. Clinical trials will commence in 2018 with CE mark and FDA 510k clearance planned for 2020.
ID-NEST is currently developping a new, disruptive way to rebuild vascular bifurcations. Targeted indications are Aortic Arch Aneurysms and Compressed Veins. Our technology focuses on a patented way to connect 2 self-expandable stents on site, in order to restore native vessel capacities.
At Karmagenes, we do behavioral genetic and psychological analysis to improve people’s personal and professional life. Karmagenes SA is a Swiss-based startup and its scientific team has developed proprietary algorithms that a) provide an unbiased view of genetic potential through DNA-based personality test, b) assess current personality through KG5+ psychological tool and c) offer custom advice through in-house psychologist regarding career orientation, partnership and wellbeing.
Since more than 450mio people have a bad mental being affecting their capacity ‘’to work and to love’’, our next step is to apply our technology to a life coaching app combining psychological and genetic data analysis coupled with artificial intelligence.
At your fingertip, you will have access to our existing network of coaches and specialists who can help you improve your overall wellbeing by understanding the real you.
The “external fixators” (FixEx) used to date have already provided the outstanding service of stabilizing bone fractures in case of serious injuries, open bone fractures and severe joint fractures for decades.With all “external fixator” systems, four to six bone pins are screwed through the skin and into the bone. A fixation device (the actual “external fixator”) is then attached to these bone pins externally. Very often so-called “trauma fixators” are then removed after a few days or weeks once the patient’s overall condition has stabilized. The bone fracture is then definitively stabilized using a plate and screws or intramedullary nails. However, mounting the “external fixator” systems that are currently on the market is enormously time-consuming and error-prone and can only be reliably implemented by experienced orthopedic surgeons.
The technical invention “snake FX” by the Erlangen-based startup nice!innovations GmbH has profoundly revolutionized the “external fixator” and its use in orthopedics and accident surgery. It is a conceptually completely new and an already well-developed product that enables an enormously clever, incomparably fast, incredibly simple method for stabilization of bone fractures by means of an unprecedented “snake principle”. Its “one-step rapid fixation technology” allows “snakeFX” to both fix the external fixator to the bone pins and stabilize the “FixEx” in a single step! Using traditional external fixator systems, both tasks involved time-consuming and error-prone mounting operations. Patents for “snake FX” have already been awarded for Europe, US, Brazil and Japan!
Precisely these unique selling points are leveraged when it comes to distribution: An initial estimate from Switzerland illustrates the high cost-saving potential combined with a dramatic increase in the quality of care for the patient. In Switzerland, one minute in the operating room costs 80 CHF. It takes trained orthopedic and trauma surgeons anywhere from 60 to 120 minutes for mounting and to make fine adjustments. The “snakeFX” aims to reduce this time to about 15 minutes.
nice!innovations GmbH is currently developing the “snakeFX” into an approved product that is ready for series production. A crowd-financing campaign on www.aescuvest.de had collected more than 260,000 euros for this purpose as of February 2016 (in the form of subordinated loans). Following successful prototyping (expected in Q3/2017), snakeFX can obtain CE approval and be prepared for series production (target Q3/2018) within 9 to 12 months. The service provider for carrying out CE certification (Risk Class 1s; assessment by the “Notified Bodies” is available) has already been commissioned; a usability study with trauma surgeons, prototype-testing in a certified testing laboratory and a clinical trial are currently being conceptualized and implemented. An investor or strategic partner is being sought for the subsequent international commercialization of “snakeFX”.
Jörg Trinkwalter is a member of the Executive Board of the cluster management organization Medical Valley Europäische Metropolregion Nürnberg (EMN) e.V., as well as registered manager of the incubator Medical Valley Center in Erlangen/Germany. Medical Valley EMN is considered as one of the most dynamic medical technology regions worldwide and was awarded national cluster of excellence by the German Ministry of Education and Research in 2010. In 2015 Jörg Trinkwalter co-founded the two medical technology startup companies nice!innovations GmbH and TBrace GmbH in the orthopedic area and acts as CEO of these companies. nice!innovations GmbH raised 262.000 € in 2016 via a crowdfinancing campaign on www.aescuvest.de in order to develop the new fixateur externe-concept “snakeFX” market-ready.
Presentation Time and Location
on 25th, during Rising European Stars Session (from 16.15 to 17.15)
Portabiles HealthCare Technologies GmbH has been founded in Nürnberg, Germany, in Dec/2016 by an experienced Management and scientific Team: Ralph Steidl (CEO), Prof. Dr. med. Jochen Klucken (University Hospital Erlangen), Prof. Dr. Björn Eskofier (University Erlangen-Nürnberg). The team works closely together since more than seven years and holds extensive competences in the fields of movement disorders, healthcare platforms, wearable technology, machine learning, data mining, and general management.
gait analysis, wearables, Medical Device, sensors, algorithms, falls prevention,
We raised in total 645.000 € through shareholder capital, convertible loans, public funding.
For medical device development, approval in Europe and US, and for sales efforts, another 1 M € are required.
Pipeline Product 1: Name/Stage
Product 1: Description
Worsening of the human gait is an important symptom in many chronic diseases and reason for most of the falls of elderly. An objective analysis of a patient's gait during activities of daily living delivers valuable information about the progress of a disease, the efficacy of a therapy (or a new drug), and the patient’s individual risk of falling. Mobile GaitLab consists of motion sensors integrated into the patient's shoes (prepared orthopedic shoes). They measure the gait dynamics and provide clinical grade gait parameters to the therapist (Medical Device class IIa). Doctors thereby will be able to adjust therapy solely based upon those data. Mobile GaitLab supports clinical trials for proving the efficacy of new drugs, tele-healthcare concepts (e.g. medication adjustment in Parkinson's Disease), and at a later stage prevention of falls.
Ralph Steidl, former Managing Director of Astrum IT (a medium sized SW company) has more than 15 years of experience in Management and Sales in IT and Telecommunication Industries and a high level of expertise in Digital Health and Medical Devises Development. He led many interdisciplinary R&D projects dealing with IT-interconnection in Healthcare and clinical grade wearable technologies.